CD34 and chronic myelogenous leukemia, BCR-ABL1 positive: However, the CD34+CD38low CML LSCs are less responsive to TKI therapy and can stay quiescent and unaffected for extended periods of time [34], resulting in enhancement of TKI resistance and relapse at the level superior of a molecular response or disease progression [69].